IDENTIFICATION OF DRUG SIDE EFFECTS USING NOVEL BIOLOGICAL NETWORK

1 K.M.DEEPA LAKSHMI
1 Research Scholar
2 Dr.A.PRAKASH
2 Professor,
1 & 2 PG & Research Department of Computer Science,
1 & 2 Hindusthan College of Arts & Science, Coimbatore ,India.

ABSTRACT

Network-based strategies are assuming an undeniably vital job in drug plan. Our primary inquiry in this paper was whether the proficiency of drug target proteins to spread irritations in the human interface is bigger if the official drugs have side effects, when contrasted with those which have no announced side effects. The results demonstrated that as a general, drug targets were better spreaders of annoyances than non-target proteins, and specifically, focuses of drugs with side effects were likewise preferable spreaders of bothers over focuses of drugs having no revealed side effects in human protein-protein connection networks. Side effects are undesirable reactions to drug treatment and are critical assets for human phenotype data. The ongoing advancement of a database on side effects, the side impact resource (SIDER), is an initial phase in recording the connection between drugs also, their side effects. It is, be that as it may, deficient to just discover the relationship of drugs with biological procedures; that relationship is critical because drugs that impact biological procedures can affect phenotype. In this manner, knowing which forms react to drugs that impact the phenotype will empower more successful and methodical investigation of the impact of drugs on phenotype. To the best of our information, the connection between biological procedures and side effects of drugs has not yet been efficiently explored.

Keywords: Drug Identification, Addicts, Side Effects, Biological Network.

1. INTRODUCTION

Throughout the most recent decade, we have seen amazing technological advances in the field of molecular biology. Huge numbers of them have presented to us an unbelievable abundance of molecular data. At first, it was trusted that expansive information driven activities, for example, the Human Genome Project would promptly make ready for the advancement of new successful treatments in biomedicine. Shockingly, the interpretation of these molecular data into biomedical achievements has been dauntingly moderate. For what reason is this so? One explanation behind this "bottleneck" is that biological procedures are very interconnected, so their manipulation is a formidable challenge. What's more, significant human sicknesses, for example, cancer, type II diabetes, and hypertension, are genetically complex. Subsequently, an immediate correspondence between causative genotype and illness phenotype, as saw in Mendelian

issue, is frequently obscure. In acknowledgment of the significance of molecular networks, researchers from various fields have started to think about them strongly through computational and exploratory means. Their fundamental preface as been that progressions to cellular networks decide numerous phenotypic varieties, and that such changes can be incited, not just by adjustments to a gene product's abundance, but also through perturbations of its communications.

The escalated enthusiasm for molecular networks has brought about systematic gathering of interaction data for biomolecules, and additionally the improvement of computational methodologies for the examination of biological networks. These days, an extensive number of freely available databases contain different kinds of molecular connection information. Networks got from these resources every now and again contain just a particular kind of molecular connection such a protein– protein or protein– DNA connections. In view of the sort of included connection, it recognize different kinds of association networks. At present, the real sorts are protein– protein interaction (PPI), gene regulatory and metabolic networks. These networks are frequently outwardly spoke to as simple graphs, with nodes or vertices denoting molecules, and links or edges denoting interactions between them. While such uncommon disentanglement dismisses numerous attributes of individual segments, it encourages the analysis and modeling of large cellular networks.

2. NETWORK-BASED APPROACHES FOR DRUG RESEARCH IDENTIFICATION OF DRUG TARGETS

The identification of drug targets is a urgent, yet relentless errand in biomedical research. These days, in silico methods can help significantly. Regular in silico methods for drug target forecast are ordinarily receptor-or ligand-based models. While receptor-based methods begin with a known structure of the target, and utilize docking to survey drug restricting ligand-based techniques include the examination of drugs with known ligands of the target protein. A fruitful case of the last technique on a genomic scale is the examination by Keiser et al. (2009), in which countless potential focuses for existing drugs were discovered dependent on substance comparability with known ligands. All the more as of late, network-based techniques have supplemented the computational toolbox for drug target identification. They are particularly useful, if the three-dimensional structure of the target is obscure. Network-based methods are propelled by the perception that the general biological significance of a protein is at any rate mostly connected to its area in relevant PPI networks.

3. ANALYSIS OF SIDE EFFECTS

Physiological side effects can be caused by authoritative of drugs to proteins ("off-focuses"), notwithstanding their proposed targets. As side effects are vital factors in helpful applications, their exact

expectation is of famous significance to stay away from disappointment in drug preliminaries. Outstandingly, deliberate chronicle of side effects speaks to a wide phenotying on the level of the human life form, giving significant comprehensive data on the activity of drugs. A one of a kind asset, with this objective, is the SIDER database, which gathers detailed side effects for very nearly 1000 advertised drugs (Kuhn et al., 2010). Utilizing this database, Mizutani et al. (2012) corresponded a drug's side effects with the proteins it ties to. For this, side effects and bound proteins were represented as binary profiles and statistically associated using a modified version of canonical correlation analysis. The acquired connection was utilized along these lines for the forecast of side effects, by assessing the proteins that the drug ties to. Surprisingly, it is similarly conceivable to anticipate a drug's objective dependent on its side effects. This relationship was initially investigated by Campillos , they distinguished new focuses of known drugs dependent on the likeness of their side effects with those of different drugs. There is currently a database, which has executed this methodology, called PROMISCUOUS . It empowers the intuitive investigation of an incorporated network of drug, protein, and side impact nodes, and can be utilized to increase new knowledge into the drug's method of activity. At long last, side effects can likewise be demonstrative for drug– drug communications, which are as often as possible of clinical importance. It was as of late demonstrated that two drugs have a tendency to communicate, if their objectives are in closeness in a PPI network, or on the off chance that they have comparative side effects. In addition, joining data on physical communication of drug targets and recorded side effects enhances the forecast exactness for drug– drug collaborations.

4. NETWORK BASED APPROACH

In the network-based methodologies depicted above, drugs fundamentally act inside little sub-networks with the end goal to "settle" or meddle with specific processes. This appears differently in relation to their ongoing use in stem cell science, where little particles have been utilized to re-wire whole cell networks. Their fundamental object in this setting is to change over (or reinvent) substantial cells, particular to a person, into stem cells. These cells may in the long run give a customized supply of tissue to recharge cells lost in degenerative illnesses. Our audit features a few uses of molecular networks, in which they go about as adaptable interfaces among phenotypes and drugs. While these applications exhibit the utility of network-based examinations, a few noteworthy difficulties still exist. Firstly, the quality and inclusion of collaboration information should be enhanced and combined.



Figure 1- Biological Network for side effects



Figure 2- from root sider data to Chem ID



Figure 3- Root node



Figure 4 –with 2 drugs



Figure 5- with 2 drugs

The research center measures presently used to assess potential antagonistic drug effects can be exorbitant and tedious. For instance, a costly two-year rat bioassay is the present best quality level for deciding the cancer-causing nature of a NCE [4]. Some examines are likewise of dicey utility - just around

15% of quality knockouts in the standard pharmaceutical model life forms demonstrate any fitness defect [3]. In this manner, drugs structured in view of a solitary target may demonstrate inadequate, not on the grounds that they don't connect with the objective in the normal way, but since of characteristic redundancies in pharmacological networks. To intensify the issue, protein-ligand examines have discovered that a solitary drug can tie focuses with incomprehensibly unique pharmacology and that around 35% of known drugs have at least two targets [5]. It isn't astounding that developmental connections may prompt shared drug-restricting abilities in protein paralogs found over an extensive variety of cell composes and biological pathways. These complexities, in any case, make new open doors for helpful methodologies including the deliberate utilization of drugs with numerous objectives to accomplish an expanded specificity basically. An ongoing audit by Giordano and Petrelli, for instance, depicts their way to deal with creating multi-target drugs for malignancy treatment while maintaining a strategic distance from drug obstruction by focusing on various tyrosine kinase receptors.

Chemical systems biology, or the utilization of systemwide devices to the examination of pharmacological reactions, can help address the absence of adequacy and undesired off-target effects . Seeing each of these requires the capacity to describe off-target side-effects in silico. In an ongoing report, Philip Bourne and have utilized a synthetic systems science way to deal with clarify the genuine side-effects of a drug that was being trialed for avoidance of cardiovascular disease.

CONCLUSION

The capacity to anticipate and even plan the effects of new drugs is basic for the future pharmaceutical industry. By incorporating biological and synthetic information, the pharmacological effects of drugs can be all the more totally comprehended and used to make prescient models. Ongoing work has concentrated on relating drugs to focuses by synthetic closeness, target auxiliary comparability and even side-impact similitude. For each situation, the outcomes have delineated the intensity of reasoning about drug reactions with regards to a network of connections, and from a systems perspective.

REFERENCES:

1. Chaurasia G., Iqbal Y., Hänig C., Herzel H., Wanker E. E., Futschik M. E. (2007). UniHI: an entry gate to the human protein interactome. Nucleic Acids Res. 35(Suppl. 1) D590–D594 10.1093/nar/gkl817 [PMC free article] [PubMed] [CrossRef]

2. Cheng F., Liu C., Jiang J., Lu W., Li W., Liu G., et al. (2012). Prediction of drug–target interactions and drug repositioning via network-based inference. PLoSComput. Biol. 8:e1002503.10.1371/journal.pcbi.1002503 [PMC free article] [PubMed] [CrossRef]

3. Csermely P., Korcsmáros T., Kiss H. J., London G., Nussinov R. (2013). Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol. Ther.138 333–408 10.1016/j.pharmthera.2013.01.016 [PMC free article] [PubMed] [CrossRef]

4. De Cegli R., Iacobacci S., Flore G., Gambardella G., Mao L., Cutillo L., et al. (2013). Reverse engineering a mouse embryonic stem cell-specific transcriptional network reveals a new modulator of neuronal differentiation. Nucleic Acids Res. 41 711–726 10.1093/nar/gks1136 [PMC free article][PubMed] [CrossRef]

5. Futschik M. E., Chaurasia G., Herzel H. (2007). Comparison of human protein–protein interaction maps. Bioinformatics 23 605–611 10.1093/bioinformatics/btl683 [PubMed] [CrossRef]

6. Gashaw I., Ellinghaus P., Sommer A., Asadullah K. (2011). What makes a good drug target? Drug Discov. Today 16 1037–1043 10.1016/j.drudis.2011.09.007 [PubMed] [CrossRef]

7. Hartwell L., Hopfield J., Leibler S., Murray A. (1999). From molecular to modular cell biology.Nature 402(Suppl.) C47–C52 10.1038/35011540 [PubMed] [CrossRef]

8. Hopkins A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 682–690 10.1038/nchembio.118 [PubMed] [CrossRef]

9. Hou P., Li Y., Zhang X., Liu C., Guan J., Li H., et al. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341 651–654 10.1126/science.1239278[PubMed] [CrossRef]

10. Huang J., Niu C., Green C. D., Yang L., Mei H, Han J.-D. J. (2013). Systematic prediction of pharmacodynamic drug–drug interactions through protein–protein-interaction network. PLoSComput. Biol. 9:e1002998. 10.1371/journal.pcbi.1002998 [PMC free article] [PubMed] [CrossRef]

11. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A. E., et al. (2008). Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. biotechnol. 26 795–797 10.1038/nbt1418 [PubMed] [CrossRef]

12. Hwang W. C., Zhang A., Ramanathan M. (2008). Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin. Pharmacol. Ther. 84 563–572 10.1038/clpt.2008.129 [PubMed] [CrossRef]

13. Iorio F., Bosotti R., Scacheri E., Belcastro V., Mithbaokar P., Ferriero R., et al. (2010). Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. U.S.A. 107 14621–14626 10.1073/pnas.1000138107 [PMC free article] [PubMed] [CrossRef]

14. Kalathur R. K., Pinto J. P., Hernández-Prieto M. A., Machado R. S., Almeida D., Chaurasia G., et al. (2014). UniHI 7: an enhanced database for retrieval and interactive analysis of human molecular interaction networks. Nucleic Acids Res. 42 D408–D414 10.1093/nar/gkt1100 [PMC free article][PubMed] [CrossRef]

15. Keiser M. J., Setola V., Irwin J. J., Laggner C., Abbas A. I., Hufeisen S. J., et al. (2009). Predicting new molecular targets for known drugs. Nature 462 175–181 10.1038/nature08506 [PMC free article] [PubMed] [CrossRef]

16. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., et al. (2011). DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39(Suppl. 1) D1035–D1041. 10.1093/nar/gkq1126 [PMC free article] [PubMed] [CrossRef]

17. Korcsmáros T., Farkas I. J., Szalay M. S., Rovó P., Fazekas D., Spiró Z., et al. (2010). Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery.Bioinformatics 26 2042–2050 10.1093/bioinformatics/btq310 [PubMed] [CrossRef]

18. Kuhn M., Campillos M., Letunic I., Jensen L. J., Bork P. (2010). A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6 343 10.1038/msb.2009.98 [PMC free article][PubMed] [CrossRef]

19. Kuhn M., Szklarczyk D., Franceschini A., von Mering C., Jensen L. J., Bork P. (2012). STITCH 3: zooming in on protein–chemical interactions. Nucleic Acids Res. 40 D876–D880 10.1093/nar/gkr1011 [PMC free article] [PubMed] [CrossRef]

20. Laenen G., Thorrez L., Börnigen D., Moreau Y. (2013). Finding the targets of a drug by integration of gene expression data with a protein interaction network. Mol. Biosyst. 9 1676–1685 10.1039/C3MB25438K [PubMed] [CrossRef]

21. Lee H. S., Bae T., Lee J. H., Kim D. G., Oh Y. S., Jang Y., et al. (2012). Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst. Biol. 6:80.10.1186/1752-0509-6-80 [PMC free article] [PubMed] [CrossRef]

22. Luo H., Chen J., Shi L., Mikailov M., Zhu H., Wang K., et al. (2011). DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical–protein

interactome. Nucleic Acids Res. 39(Suppl. 2) W492–W498 10.1093/nar/gkr299 [PMC free article][PubMed] [CrossRef]

23. Manolio T. A. (2010). Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363 166–176 10.1056/NEJMra0905980 [PubMed] [CrossRef]

24. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, Mikhailov D, Whitebread S, Hamon J, Azzaoui K, Urban L, Glick M, Davies JW, Jenkins JL: Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J ChemInf Model. 2009, 49: 308-317. 10.1021/ci800344p.PubMedView ArticleGoogle Scholar

25. Fosnocht D, Taylor JR, Caravati EM: Emergency department patient knowledge concerning acetaminophen (paracetamol) in over-the-counter and prescription analgesics. Emerg Med J. 2008, 25: 213-216. 10.1136/emj.2007.053850.PubMedView ArticleGoogle Scholar

26. Hopkins AL: Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008, 4: 682-690. 10.1038/nchembio.118.PubMedView ArticleGoogle Scholar

27. Plant N: Can systems toxicology identify common biomarkers of non-genotoxic carcinogenesis?. Toxicology. 2008, 254: 164-169. 10.1016/j.tox.2008.07.001.PubMedView ArticleGoogle Scholar

28. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK: Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007, 25: 197-206. 10.1038/nbt1284.PubMedView ArticleGoogle Scholar

29. Petrelli A, Giordano S: From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008, 15: 422-432. 10.2174/092986708783503212.PubMedView ArticleGoogle Scholar

30. Xie L, Li J, Xie L, Bourne PE: Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoSComput Biol. 2009, 5: e1000387-10.1371/journal.pcbi.1000387.PubMedPubMed CentralViewArticleGoogle Scholar

31. Peterson RT: Chemical biology and the limits of reductionism. Nat Chem Biol. 2008, 4: 635-638. 10.1038/nchembio1108-635.PubMedView ArticleGoogle Scholar

32. Lee JM, Gianchandani EP, Papin JA: Flux balance analysis in the era of metabolomics. Brief Bioinformatics. 2006, 7: 140-150. 10.1093/bib/bbl007.PubMedView ArticleGoogle Scholar

33. McAdams HH, Shapiro L: Circuit simulation of genetic networks. Science. 1995, 269: 650-656. 10.1126/science.7624793.PubMedView ArticleGoogle Scholar

34. Peleg M, Rubin D, Altman RB: Using Petri Net tools to study properties and dynamics of biological systems. J Am Med Inform Assoc. 2005, 12: 181-199. 10.1197/jamia.M1637.PubMedPubMed CentralViewArticleGoogle Scholar

35. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13: 2498-2504. 10.1101/gr.1239303.PubMedPubMed CentralViewArticleGoogle Scholar

36. Clément-Ziza M, Malabat C, Weber C, Moszer I, Aittokallio T, Letondal C, Rousseau S: Genoscape: a Cytoscape plug-in to automate the retrieval and integration of gene expression data and molecular networks. Bioinformatics. 2009Google Scholar

37. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA: Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008, 4: 691-699. 10.1038/nchembio.117.PubMedPubMed CentralViewArticleGoogle Scholar

38. Scheiber J, Jenkins JL, Sukuru SC, Bender A, Mikhailov D, Milik M, Azzaoui K, Whitebread S, Hamon J, Urban L, Glick M, Davies JW: Mapping adverse drug reactions in chemical space. J Med Chem. 2009, 52: 3103-3107. 10.1021/jm801546k.PubMedView ArticleGoogle Scholar

39. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P: Drug target identification using side-effect similarity. Science. 2008, 321: 263-266. 10.1126/science.1158140.PubMedView ArticleGoogle Scholar

40. Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK: Quantifying the relationships among drug classes. J ChemInf Model. 2008, 48: 755-765. 10.1021/ci8000259.PubMedPubMed CentralViewArticleGoogle Scholar

41. Pathguide: the pathway resource list. [http://www.pathguide.org]

42. Blow N: Systems biology: untangling the protein web. Nature. 2009, 460: 415-418. 10.1038/460415a.PubMedView ArticleGoogle Scholar

43. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P: STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 2008, D684-D688. 36 DatabaseGoogle Scholar

44. Hansen N, Brunak S, Altman R: Generating genome-scale candidate gene lists for pharmacogenomics. ClinPharmacolTher. 2009, 86: 183-189. 10.1038/clpt.2009.42.PubMedPubMed CentralViewArticleGoogle Scholar